RxDoctor Payments Data

Mohammad Ansari, MD

Psychiatry · Manassas, VANPI 1891874863

Payments from drug & device makers

$2,533in general payments, 2019–2025

Across 142 payments — averaging $17.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$664
  • Johnson & Johnson$488
  • Alkermes, Inc.$285
  • Integra Lifesciences Corporation$227
  • Sunovion Pharmaceuticals Inc.$170
  • Otsuka America Pharmaceutical, Inc.$143
  • plus $556 from 9 others

What the payments were for

  • Food & beverage$2,49598%
  • Education$382%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,533 in reported general payments places this provider in the 85th percentile of 884 psychiatry providers in Virginia.

See all psychiatry providers in Virginia

Medicare billing

Part B allowed, 2024
$9,233
Medicare patients
25
Services billed
165

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate45$102,899
AristadaAripiprazole Lauroxil12$40,651
VraylarCariprazine Hcl18$25,074
Risperdal ConstaRisperidone Microspheres12$22,859
TrintellixVortioxetine Hydrobromide16$12,623
Divalproex Sodium22$3,555
Quetiapine Fumarate68$3,109
Desvenlafaxine Succinate ErDesvenlafaxine Succinate25$1,563
Olanzapine56$997
Divalproex Sodium ErDivalproex Sodium19$713
Benztropine Mesylate62$708
Ziprasidone Hcl14$697
Haloperidol Decanoate19$691
Lithium Carbonate ErLithium Carbonate39$580
Aripiprazole32$555

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Risperdal Consta$488$125,75857 claims
Alkermes, Inc.Aristada$285$40,65112 claims
AbbVieVraylar$664$25,07418 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$76$12,62316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 884 psychiatry providers in Virginia.

Other psychiatry in Manassas

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →